Compare Cigna Corp (CI) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Raytheon Technologies Corp — how do they compare? Cigna Corp trades at $272.52 (market cap $73.56B), while Raytheon Technologies Corp trades at $223.85 (market cap $302.06B). The key difference: Raytheon Technologies Corp is far larger — about 4.1× Cigna Corp's market cap, and Cigna Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| CI | RTX | |
|---|---|---|
Market Cap | $73.56B | $302.06B |
Sector | Health | Industrials |
52-Week High | $311.00 | $224.12 |
52-Week Low | $244.41 | $151.75 |
Enterprise Value | $98.27B | $332.61B |
Dividend Yield | 2.24% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
RTX trades at $223.03, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a recent $515 million Navy radar contract. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $88.6 billion in 2025, and net income margin improved to 8.28%. The stock is near its consensus price target of $233.14, with no analyst sell ratings.
The outlook for RTX is positive, driven by defense contract wins and expanding profit margins, but risks include high valuation multiples and geopolitical uncertainties. Earnings growth and execution on backlog are key catalysts for further upside, though the stock's elevated P/E ratio of 39.27 warrants caution amid potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
